"GENECAST signed a Memorandum of Understanding (MOU) with MediCheck...This MOU emphasizes mutual cooperation for the early detection of cancer through ctDNA liquid biopsy...The first phase of this joint research will be a clinical study to assess the effectiveness of early detection. This study targets high-risk individuals with nodules of a certain size visible on LDCT, aiming to detect key lung cancer gene mutations such as EGFR and KRAS."